Associations between serum levels of calcium, parathyroid hormone and future risk of venous thromboembolism: The Tromso study

European Journal of Endocrinology

Volumn 176, Issue 5, 2017, Pages 625-634

  Lerstad, Gunhild ^a   Brodin, Ellen E ^a,c   Svartberg, Johan ^a,b   Jorde, Rolf ^a,b   Brox, Jan ^a,b   Brækkan, Sigrid K ^a,b   Hansen, John Bjarne ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; EXPOSURE; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH SURVEY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; POPULATION BASED CASE CONTROL STUDY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REFERENCE VALUE; SERUM; TIME; VENOUS THROMBOEMBOLISM; BLOOD; NORWAY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; NORWAY; PARATHYROID HORMONE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 85016414558     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-16-1037     Document Type: Article

References (43)

1. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS & Melton LJ 3rd. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. Journal of Bone and Mineral Research 2006 21 171-177. (doi:10.1359/JBMR.050910)
2. Bouillon R, Carmeliet G & Boonen S. Ageing and calcium metabolism. Baillieres Journal of Endocrinology and Metabolism 1997 11 341-365. (doi:10.1016/S0950-351X (97) 80332-1)
3. Chertok-Shacham E, Ishay A, Lavi I & Luboshitzky R. Biomarkers of hypercoagulability and inflammation in primary hyperparathyroidism. Medical Science Monitor 2008 14 CR628-CR632.
4. Erem C, Kocak M, Hacihasanoglu A, Yilmaz M, Saglam F & Ersoz HO. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels. Experimental and Clinical Endocrinology and Diabetes 2008 116 619-624. (doi:10.1055/s-2008-1065365)
5. Erem C, Kocak M, Nuhoglu I, Yilmaz M & Ucuncu O. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. European Journal of Endocrinology 2009 160 863-868. (doi:10.1530/EJE-09-0069)
6. Lind L, Skarfors E, Berglund L, Lithell H & Ljunghall S. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. Journal of Clinical Epidemiology 1997 50 967-973. (doi:10.1016/S0895-4356 (97) 00104-2)
7. Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, Melhus H, Held C, Lind L, Michaelsson K et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009 119 2765-2771. (doi:10.1161/CIRCULATIONAHA.108.808733)
8. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. Journal of Thrombosis and Haemostasis 2005 3 1611-1617. (doi:10.1111/j.1538-7836.2005.01415.x)
9. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM & Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Archives of Internal Medicine 1998 158 585-593. (doi:10.1001/archinte.158.6.585)
10. Glynn RJ & Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. American Journal of Epidemiology 2005 162 975-982. (doi:10.1093/aje/kwi309)
11. Robetorye RS & Rodgers GM. Update on selected inherited venous thrombotic disorders. American Journal of Hematology 2001 68 256-268. (doi:10.1002/ajh.10002)
12. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999 353 1167-1173. (doi:10.1016/S0140-6736 (98) 10266-0)
13. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P & Folsom AR. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. American Journal of Medicine 2004 117 19-25. (doi:10.1016/j.amjmed.2004.01.018)
14. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, Prins MH & Girolami A. An association between atherosclerosis and venous thrombosis. New England Journal of Medicine 2003 348 1435-1441. (doi:10.1056/NEJMoa022157)
15. White RH. The epidemiology of venous thromboembolism. Circulation 2003 107 I4-I8. (doi:10.1161/01.cir.0000078468.11849.66)
16. Nossent AY, Eikenboom JC & Bertina RM. Plasma coagulation factor levels in venous thrombosis. Seminars in Hematology 2007 44 77-84. (doi:10.1053/j.seminhematol.2007.01.006)
17. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N & Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). American Journal of Medicine 2002 113 636-642. (doi:10.1016/S0002-9343 (02) 01345-1)
18. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T & Njolstad I. Cohort profile: the Tromso study. International Journal of Epidemiology 2012 41 961-967. (doi:10.1093/ije/dyr049)
19. Borch KH, Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J & Hansen JB. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromso study. Journal of Thrombosis and Haemostasis 2009 7 739-745. (doi:10.1111/j.1538-7836.2008.03234.x)
20. Kronborg J, Solbu M, Njolstad I, Toft I, Eriksen BO & Jenssen T. Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. Nephrology Dialysis Transplantation 2008 23 2818-2826. (doi:10.1093/ndt/gfn148)
21. Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J & Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromso study, Tromso, Norway. Journal of Thrombosis and Haemostasis 2010 8 157-162. (doi:10.1111/j.1538-7836.2009.03498.x)
22. Rinde LB, Smabrekke B, Mathiesen EB, Lochen ML, Njolstad I, Hald EM, Wilsgaard T, Braekkan SK & Hansen JB. Ischemic stroke and risk of venous thromboembolism in the general population: the Tromso study. Journal of the American Heart Association 2016 5. (doi:10.1161/JAHA.116.004311)
23. Rinde LB, Lind C, Smabrekke B, Njolstad I, Mathiesen EB, Wilsgaard T, Lochen ML, Hald EM, Vik A, Braekkan SK et al. Impact of incident myocardial infarction on the risk of venous thromboembolism: the Tromso study. Journal of Thrombosis and Haemostasis 2016 14 1183-1191. (doi:10.1111/jth.13329)
24. Blix K, Braekkan SK, le Cessie S, Skjeldestad FE, Cannegieter SC & Hansen JB. The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromso study. European Journal of Epidemiology 2014 29 277-284. (doi:10.1007/s10654-014-9902-7)
25. Blondon M, Rodabough RJ, Budrys N, Johnson KC, Berger JS, Shikany JM, Raiesdana A, Heckbert SR, Manson JE, LaCroix AZ et al. The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism. From the Women's Health Initiative Randomized Controlled Trial. Journal of Thrombosis and Haemostasis 2015 113 999-1009. (doi:10.1160/TH14-05-0478)
26. van Ballegooijen AJ, Reinders I, Visser M & Brouwer IA. Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. American Heart Journal 2013 165 655-664, 664.e651-e655. (doi:10.1016/j. ahj.2013.02.014)
27. Reid IR, Gamble GD & Bolland MJ. Circulating calcium concentrations, vascular disease and mortality: a systematic review. Journal of Internal Medicine 2016 279 524-540. (doi:10.1111/joim.12464)
28. Jorde R, Bonaa KH & Sundsfjord J. Population based study on serum ionised calcium, serum parathyroid hormone, and blood pressure. The Tromso study. European Journal of Endocrinology 1999 141 350-357. (doi:10.1530/eje.0.1410350)
29. Jorde R, Sundsfjord J, Fitzgerald P & Bonaa KH. Serum calcium and cardiovascular risk factors and diseases: the Tromso study. Hypertension 1999 34 484-490. (doi:10.1161/01. HYP.34.3.484)
30. Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J & Hansen JB. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. Journal of Thrombosis and Haemostasis 2008 6 1851-1857. (doi:10.1111/j.1538-7836.2008.03102.x)
31. Lind C, Enga KF, Mathiesen EB, Njolstad I, Braekkan SK & Hansen JB. Family history of myocardial infarction and cause-specific risk of myocardial infarction and venous thromboembolism: the Tromso study. Circulation Cardiovascular Genetics 2014 7 684-691. (doi:10.1161/CIRCGENETICS.114.000621)
32. Quist-Paulsen P, Naess IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR & Hammerstrom J. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica 2010 95 119-125. (doi:10.3324/haematol.2009.011866)
33. Braekkan SK, Hald EM, Mathiesen EB, Njolstad I, Wilsgaard T, Rosendaal FR & Hansen JB. Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 487-491. (doi:10.1161/ATVBAHA.111.237545)
34. Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P & Rastad J. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clinical Endocrinology 2002 56 253-260. (doi:10.1046/j.0300-0664.2001.01468.x)
35. Sorensen HT, Horvath-Puho E, Sogaard KK, Christensen S, Johnsen SP, Thomsen RW, Prandoni P & Baron JA. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. Journal of Thrombosis and Haemostasis 2009 7 521-528. (doi:10.1111/j.1538-7836.2009.03279.x)
36. Sorensen HT, Horvath-Puho E, Lash TL, Christiansen CF, Pesavento R, Pedersen L, Baron JA & Prandoni P. Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation 2011 124 1435-1441. (doi:10.1161/CIRCULATIONAHA.111.025627)
37. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. New England Journal of Medicine 2005 352 373-379. (doi:10.1056/NEJMcp042806)
38. Andreescu AC, Cushman M & Rosendaal FR. D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia study. Journal of Thrombosis and Haemostasis 2002 87 47-51.
39. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ & Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010 116 113-121. (doi:10.1182/blood-2010-02-267740)
40. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM & Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003 101 4387-4392. (doi:10.1182/blood-2002-10-3188)
41. Wulaningsih W, Sagoo HK, Hamza M, Melvin J, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, Walldius G et al. Serum calcium and the risk of breast cancer: findings from the Swedish AMORIS study and a meta-analysis of prospective studies. International Journal of Molecular Sciences 2016 17. (doi:10.3390/ijms17091487)
42. Schattner A, Dubin I, Huber R & Gelber M. Hypocalcaemia of malignancy. Netherlands Journal of Medicine 2016 74 231-239.
43. Jorde R, Svartberg J & Sundsfjord J. Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. Journal of Hypertension 2005 23 1639-1644. (doi:10.1097/01. hjh.0000179764.40701.36)